FDA approves Farxiga

|By:, SA News Editor

The FDA approves AstraZeneca (AZN +0.3%) and Bristol-Myers Squibb's (BMY +1.2%) Farxiga (dapaglifozin).

The drug is intended to improve glycemic control in adults with Type 2 diabetes.

Farxiga isn't recommended for patients with active bladder cancer and the regulator is "requiring six post-marketing studies," including a CVOT.

FDA PR